Executive readout · one minute
What the filings say
- 10-Q report · filed Nov 5, 2026
- Intellia Therapeutics said the FDA accepted lonvo-z’s BLA, granted Priority Review and set a March 10, 2027 target action date, supporting a planned first quarter 2027 U.S. launch if approved.
The audio replay and transcript follow the call.